Cultured skin fibroblasts or lymphoblastoid cells from eight patients with clinical symptoms of prolidase deficiency were analyzed in terms of enzyme activity, presence of material crossreacting with specific antibodies, biosynthesis of the polypeptide, and mRNA corresponding to the enzyme. There are at least two enzymes that hydrolyze imidodipeptides in these cells and these two enzymes could be separated by an immunochemical procedure. The specific assay for prolidase showed that the enzyme activity was virtually absent in six cell strains and was markedly reduced in two (< 3% of controls). The activities of the labile enzyme that did not immunoprecipitate with the anti-prolidase antibody were decreased in the cells (30-60% of controls).
Introduction
Prolidase deficiency is an autosomal recessive disorder characterized by mental retardation, various skin lesions, and abnormalities of collagenous tissues (1 sis of di-and tripeptides with carboxy-terminal proline and seems to play an important role in the recycling of proline. As a consequence of the deficiency of prolidase, massive imidopeptiduria and relatively lowered levels of plasma proline are present in the patients (1) . The precise mechanisms involved in the development of skin lesions, mental retardation, and other symptoms including splenomegaly, osteoporosis, and frequent infections have not been completely elucidated.
More than 20 cases of prolidase deficiency have been reported, and some of the patients had no clinical symptoms of the disease (2, 3) . The symptoms do not seem to be related to severities produced by the enzyme defect, as deduced from individual case reports. Clinical symptoms appear gradually; hence, an assessment of the symptoms at the time of the diagnosis or during the relatively short period of the investigations is difficult. The hydrolytic activities toward imidodipeptides in crude extracts of tissues and cells may not solely represent the activity of a single enzyme (4) and activities of prolidase in cases of a deficiency may not reflect residual activities of prolidase itself, which is genetically defective.
We purified human prolidase to apparent homogeneity and prepared anti-prolidase monoclonal and polyclonal antibodies for use in the immunochemical analysis of prolidase deficiency (5) . Boright et al. (6) most recently developed a polyclonal antibody directed against prolidase and used it to analyze cells from prolidase-deficient patients. We used the antibodies to identify a cDNA clone corresponding to the human prolidase mRNA (7) . Based on the partial amino acid sequence of the purified enzyme and the nucleotide sequence of the cDNA clones, the primary structure of human prolidase has been deduced (8) .
We have now examined the biochemical basis of prolidase deficiency using cultured skin fibroblasts or cultured lymphoblastoid cells obtained from subjects from families with prolidase deficiency. The availability of the specific antibodies and the cloned cDNA facilitated a definition of the polypeptide and RNA phenotypes of these patients. The biochemical and clinical phenotypes were compared. Methods Materials. IgG-EP2, EP1O , and EP38 mouse MAbs that bind to human prolidase, and IgG-NR, a control mouse MAb directed against an irrelevant antigen, were prepared by the hybridoma technique described elsewhere (5) . Human prolidase was then purified from peripheral erythrocytes using an immunoaffinity gel (9) . Polyclonal antiserum was developed in rabbits by injecting purified human prolidase. Prolidase-Sepharose 4B was prepared using cyanogen bromide-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) according to the manufacturer's description. The gel preparation containing 2 mg of purified prolidase per ml of Sepharose 4B was used to isolate the specific IgG that binds to prolidase from the anti-prolidase rabbit serum. Immobilized mouse IgGs on agarose beads were prepared using purified IgGs and cyanogen bromide-activated Sepharose 4B (1 mg of purified IgG per ml).
The cDNA insert (PL-2 1) corresponding to human prolidase mRNA was cloned and characterized (8) . It was found to cover nearly the full length of the coding region and 3' noncoding region of the mRNA and was used as a probe for RNA blotting analysis. The DNA probe was radiolabeled as described (10) . [a-32P]CTP (3, The nitrocellulose membranes were incubated with 0.5-1 gg/ml antiprolidase rabbit IgG. The rabbit IgG was detected as described (5 (8) . Enzyme assay. Imidodipeptide-hydrolyzing activities were measured using glycyl-L-proline, L-alanyl-L-proline, and L-leucyl-L-proline as substrates. The activities in the crude cell extracts were measured at 370C in a total vol of 250 ul containing 0.1 M Tris-HCl, pH 8.0, 10 mM MnCl2, and 10 mM of a substrate peptide after 15 min of preincubation unless otherwise stated. The proline released from the peptides was assayed by the method of Chinard ( 16) as described ( 17).
For the immune titration of prolidase activity, various amounts of mouse or rabbit IgG were incubated with the crude cell extracts for 1 h at room temperature and a 50-id suspension of protein A agarose (1:1) was added. The enzyme activity in the supernatant was then measured. The enzyme activity that bound to mouse IgG EP2 was measured as follows: the samples were prepared by incubating the crude cell extracts and EP2-agarose at room temperature for 1 h. The gel was washed three times with 50 mM Tris-HCl, pH 7.6, containing 10 mM MnC12. The gel suspension was preincubated for 15 min at 370C and the substrate peptides were added. After an appropriate incubation time at 37°C, with vigorous shaking, the supernatant was collected and used for the determination of proline. Mouse IgG EP2 did not inhibit the enzyme activity of prolidase. Alternatively, the prolidase was eluted from the gel with 0.1 M Na2CO3 for enzyme assay (9) .
Patients. Cultured skin fibroblasts or cultured lymphoblastoid cells were obtained from eight patients with prolidase deficiency. Clinical features are summarized in Table I . Two patients died (cases 2 and 4) ;and skin lesions were present in all the patients. In severe cases there were deep skin ulcers or lymphedema. Mild skin lesions included eruption, teleangiectagia, and pigmentation. Two ofthe first cousins of the case 5 patient had a prolidase deficiency with similar skin lesions and other clinical features. Skin lesions of the case 7 patient were present from 19 mo, while her sister (case 8) had no prominent changes in the skin until 18 yr.
Results Fig. 1 A shows the immune titration of imidodipeptide-hydrolyzing activities with mouse IgG EP2 in crude extracts from a control fibroblast cell strain. Most of the imidodipeptide-hydrolyzing activity was immunoprecipitated. When the enzyme activity in the supernatant was measured without preincubation a small amount ofactivity was detected (Tables II and III) . This activity remained in the supernatant after immunoprecipitation with the polyclonal rabbit IgG or other monoclonal mouse IgGs (EP1O and EP38). The activity of prolidase was not inhibited when mouse IgG-EP2 was added to the mixture ( Fig. 1 A) . As described below, the substrate specificities of the activities in the supernatant and in the immunoprecipitates differed. L-Alanyl-L-proline was used as a substrate in this experiment, since this peptide was suitable to detect both activities.
Immunoblot analyses of the immunoprecipitated fraction and the supernatant obtained from the control cells are shown in Fig. 1 B. The precipitate contained a protein of M, 56,000 that crossreacted with the polyclonal antibody. The supernatant, however, did not. The M, 56,000 protein was the subunit derived from prolidase (5, 9) . The imidodipeptide-hydrolyzing activity in the supernatant showed a different substrate specificity from the immunoprecipitated enzyme (Table II) . The enzyme activity in the supernatant seemed to correspond to the labile enzyme reported by Butterworth and Priestman (4). The labile enzyme could be separated from prolidase by DEAE cellulose column chromatography (4) . We confirmed that the labile enzyme did not crossreact with antiprolidase monoclo- nal and polyclonal antibodies. Thus, the activity in the supernatant obtained after the immunoprecipitations represented the labile imidodipeptidase. The crude extracts from the controls' and patients' cells were subjected to immunoprecipitation. The enzymic activities remaining in the supernatant were measured using glycyl-L-proline, L-alanyl-L-proline, and L-leucyl-L-proline as substrates (Tables II and HII) . In cases 1 and 2 part of the activity toward glycyl-L-proline or leucyl-L-proline was immunopre- Tables II   and III) . The immune complexes prepared with EP2-agarose and the crude extracts of the cell strains of cases 1 and 2 contained imidodipeptide-hydrolyzing activity (Table II) . The enzyme from case 1 preferentially hydrolyzed glycyl-L-proline and the enzyme from case 2, L-leucyl-L-proline (Table II) . These activities seemed to represent the mutant enzymes in these two cell strains. The activity associated with EP2-agarose could be eluted with 0.1 M Na2CO3 without loss of the activity. The putative-mutant enzymes were eluted from EP2-agarose and studied for substrate specificities. The activities and the substrate specificities of the enzymes in each cell strain were similar to those obtained using immune complexes (not shown).
Immune proteins precipitated with EP2-agarose from the cultured fibroblasts and lymphoblastoid cells were studied by immunoblotting (Fig. 2, A, C , and E). In the lane related to control cells, a protein with M, 56,000 was specifically stained.
Samples from cases 1 and 2 contained immunologically crossreacting materials (CRM).' Sizes of the CRM were the same as that of the control. In other experiments the crude extracts of the cultured cells were analyzed directly by immunoblotting (Fig. 2, B, D, and F) . These results suggest that cells from cases 3-8 patients did not contain CRM when examined using immunoblots. An analysis of erythrocytes from the case 6 patient revealed the absence of CRM (not shown).
Metabolic labeling of the fibroblasts followed by immunoprecipitation of prolidase was done to investigate the biosyn- 7 and 8) were analyzed by metabolic labeling (Fig. 4) Northern blot hybridization was used to determine prolidase gene expression in the fibroblast cell strains and lymphoblastoid cell strains (Fig. 5) . A cDNA insert that covered most of the coding region and the 3' noncoding region was radiolabeled and used as a probe. In the lane containing the total RNA from the control cells a 2.3-kb band was observed. Lanes that contained the same amount of total RNA showed a radiolabeled band of the same size (cases I and 2). On the other hand, mRNA corresponding to prolidase was not detected in cells from other patients. RNA preparations from the fibroblast strains of cases 7 and 8 were not available.
Thus, we analyzed eight cell strains from seven families with clinically manifested prolidase deficiency. Two were CRM positive and the others were CRM negative. CRM-positive cells possessed weak but detectable activities of prolidase. CRM-negative cell strains were mRNA negative. The biochemical phenotypes are summarized in Table IV .
Discussion
Our series of experiments revealed that human prolidase is a homodimer with an estimated Mr of 56,000 as determined by SDS-PAGE (5, 9) , and the subunit composed of 492 amino acid residues has an Mr of 54,305 (8) . The cDNA codes 493 amino acid residues, and in the mature enzyme the NH2-terminal methionine is removed and the newly appearing NH2-terminal alanine is acylated, probably acetylated (8) . There is no evident processing on the carboxyl terminus and there are two possible glycosylation sites on the polypeptide (8) . We observed biosynthesis of prolidase within fibroblasts and lymphoblasts from controls. Pulse and chase experiments revealed that the subunit of prolidase is synthesized as a polypeptide with Mr 56,000, similar to findings with the purified enzyme (5, 9) . These findings are compatible with data obtained in studies on fibroblasts (6) . All these results suggest that both the processing of the polypeptide (as expected from the previous study) and glycosylation were minimal.
We reported that the subunit protein of prolidase was absent in erthrocytes of a Japanese subject with prolidase deficiency (5 The genetic heterogeneity in prolidase deficiency was demonstrated by the specific assay of prolidase, immunoblot, and metabolic labeling analyses of the enzyme protein, and analyses of mRNA by Northern blotting in the cultured cells. Two ofthe eight patients were CRM positive. In the two CRM-positive cell strains, biosynthesis of the polypeptides was similar to that of control; hence, there may be a single amino acid substitution among the mutant enzymes. These results are in accord with those obtained from immunoblot analyses in which the decreased amount ofthe Mr 56,000 polypeptide was specifically demonstrated in both cell types. Northern blots revealed a normal size of mRNAs in both cell types. The difference in substrate specificities seen with the two mutant enzymes may indicate different mutations, although the active site of the enzyme does relate to both mutations. Boright et al. (6) reported a case with high molecular weight polypeptide that crossreacted with anti-prolidase antibody. These data indicate that a genetic heterogeneity is present among the CRM-positive patients.
These studies support the proposal that prolidase deficiency is caused by a genetic defect within the prolidase gene. Prolidase deficiency is a syndrome characterized by a variety of abnormalities in organs and tissues. One of the main questions is whether the disorder is caused by a defect in the prolidase gene or whether another gene is involved. Prolidase was absent in the mRNA in four patients with prolidase deficiency. Thus, the defect in the protein might be associated with a defect in expression ofthe gene. The abnormal enzymes in two patients suggest that the mutations might be localized at the prolidase gene.
Severities of enzyme defects have been speculated, based on results of prolidase assays with extracts from cells including peripheral erythrocytes (2, 3, (17) (18) (19) (20) (21) , leukocytes (21, 22), cultured skin fibroblasts (4, 18, 23, 24) , and cultured lymphoblastoid cells (18). However, human cells contain a labile activity other than prolidase toward imidodipeptides (4, 23) and levels of the labile activity vary with the cell and tissue (4) . As a specific assay of prolidase was required to assess severity ofthe enzyme defects, we made use of an immunochemical proce- The age at onset of the clinical symptoms did not correlate with the severity of the enzyme defect. The mental development possibly reflects the severity of the biochemical defect since mental retardation occurred only in the CRM-negative patients; however, the absence of CRM is not always associated with mental retardation. The mutant prolidases in the CRM-positive cells showed low levels of enzyme activity, but this residual activity may be too minimal to alter imidodipeptide metabolism in the skin and collagenous tissues.
The labile enzyme probably plays some role in metabolism of the imidodipeptides. Our study provided evidence that the labile enzyme is not immunologically related to prolidase. These two enzymes, the prolidase and the labile enzyme, represent different polypeptides; hence, the structural gene must be different.
Butterworth and Priestman (4) described abnormal natures of the labile enzyme in prolidase-deficient cells. Boright et al. (6) reported that the hydrolyzing activity against glycyl-L-proline was -5% normal in CRM-negative cells, thereby indicating the presence of the labile enzyme. Our approaches, presented in this study, facilitated assessment ofthe activity ofthe labile enzyme even in the control and the CRM-positive cells. Our data show that the labile activities are equally decreased in CRM-positive and -negative cells. However, these enzyme assays do not allow for estimation of the total imidopeptidehydrolyzing activity in vivo in the patients and the control. labile enzyme is limited. Butterworth and Priestman speculated, based on their observations, that the labile enzyme and prolidase might possess a common subunit (4). However, our observations ruled out this possibility. We assume that prolidase may be related to the stability ofthe labile enzyme in vivo or that gene regulation ofthe labile enzyme may be influenced by factors that relate to prolidase activity.
Regarding the clinical heterogeneity of prolidase deficiency, the role of the labile enzyme has to be clarified. It is tempting to speculate that among individuals with a prolidase deficiency and various activities of the labile enzyme, those with decreased levels may develop clinical symptoms of prolidase deficiency. However, our data of the siblings (cases 7 and 8 of prolidase deficiency with different degrees of severity of skin lesions) do not support this proposal. The case 7 patient developed skin lesions at age 19 mo and specific treatment was required, whereas her sister (case 8) had no prominent change in the skin until age 18 yr. Both were CRM negative and there were no residual activities of prolidase in the fibroblasts. The total imidopeptide-hydrolyzing activities of two cell strains were similar (Table II) . The imidodipeptide-hydrolyzing activities in sera of siblings was reported to be similar (25). These activities in the sera may represent the labile enzyme since these two patients were CRM negative and the substrate specificity of the activity resembled that of the labile enzyme (25). The labile enzyme in this family may not itself be a major factor modifying development of skin lesions.
Thus, our data suggest that the labile enzyme seems to be largely irrelevant as a biochemical basis for this metabolic disorder. Further studies are needed to clarify the mechanisms of the heterogeneous expression of the genetic defects in relation to this specific disorder.
Cloning of genomic DNA for the prolidase gene is ongoing in our laboratory. The prolidase gene is extremely large in humans and possible pseudogenes have to be identified (Tanoue, A., F. Endo, and I. Matsuda, manuscript in preparation).
